Related Experiment Videos
Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis
Yi Zhou1, Yang Yuan, Rong-Rong Cai
1The Affiliated ZhongDa Hospital of Southeast University, Department of Endocrinology, No. 87 DingJiaQiao Road, Nanjing, 210009, PR China. zhouyi521520@163.com
Expert Opinion on Pharmacotherapy
|July 6, 2013
Summary
Statin therapy does not significantly impact glycaemic control in type 2 diabetes patients. Specific statins like atorvastatin may worsen HbA1c, while simvastatin shows improvement.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Randomized controlled trials (RCTs) confirm cardiovascular benefits of statin therapy in type 2 diabetes.
- Recent studies suggest statins may increase diabetes risk by 9%.
Purpose of the Study:
- To investigate the effect of statin therapy on glycaemic control in patients with type 2 diabetes using a meta-analysis.
Main Methods:
- A systematic search of Medline, EMBASE, and Cochrane Central Register of Controlled Trials was conducted for RCTs involving statins and type 2 diabetes.
- Random-effect meta-analysis was employed to calculate mean differences for glycaemic parameters, with heterogeneity assessed using the I² statistic.
Main Results:
- The meta-analysis included 26 studies with 3232 participants.
- Statin therapy showed no significant effect on HbA1c, fasting plasma glucose (FPG), body mass index (BMI), fasting insulin, or HOMA-IR.
- Subgroup analysis revealed atorvastatin negatively impacted HbA1c, whereas simvastatin demonstrated a beneficial effect.
Conclusions:
- Statin therapy does not significantly alter glycaemic control in individuals with type 2 diabetes.
- Statin use can continue for patients with moderate to high cardiovascular risk or existing cardiovascular disease without concern for glycaemic control changes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...